Table 2. Prevalence rate (and the related 95% CI) of HPV infections sustained by vaccine, G1 or HR-types, by single HPV-type or multiple HPV-types, in the HPV-typed women and in the entire cohort.
| N positive women | Prevalence rate (among 76 women with a typed HPV infection) | 95% CI | Prevalence rate (on the entire cohort, 796) | 95% CI | |
|---|---|---|---|---|---|
| HPV-6/11/16/18 | 24 | 31.58 | 22.13–42.03 | 3.02 | 1.83–4.20 |
| HPV-16/18 | 16 | 21.05 | 11.89–30.22 | 2.01 | 1.04–2.99 |
| HPV-HR G1* | 60 | 78.95 | 69.78–88.11 | 7.54 | 5.70–9.37 |
| any HR-HPV^ | 72 | 94.74 | 89.72–99.76 | 9.05 | 7.05–11.04 |
| Only LR-HPV | 4 | 5.26 | 0.24–10.28 | 0.50 | 0.01–0.99 |
| Single HPV | 38 | 50.00 | 46.53–53.47 | 4.77 | 3.29–6.26 |
| Multiple HPV | 38 | 50.00 | 46.53–53.47 | 4.77 | 3.29–6.26 |
*G1 types (carcinogenic to humans) include: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59. ^Any HR types include G1 (carcinogenic to humans); G2A (probably carcinogenic to humans): HPV-68; G2B (possibly carcinogenic to humans): HPV-26, -30, -34, -53, -66, -67, 69, -70, -73, -82, -- 85, -97.